Month: March 2022

Initiation of the NATiV3 Phase III clinical trial with lanifibranor in NASHReceipt of a €4 m milestone payment from AbbVie following the inclusion of the first patient in the ongoing Phase IIb clinical trial with cedirogant1 in patients with moderate to severe psoriasisR&D expenses doubled for full year 2021 reaching €48.4 m compared to 2020, mainly driven by the preparation and initiation of the NATiV3 Phase III clinical trial Cash position2 at €95.4 m as of December 31, 2021 compared to €113.0 m as of December 31, 2020 Implementation of an At-The-Market (“ATM”) program in the United States for the sale up to $100 m of ADSDaix (France), Long Island City (New York, United States), March 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of...

— Exceeds Mid-point of Oil Sales Volume Guidance for Q4 2021 —— Targeting $100 Million Share Repurchase Program and Quarterly Dividend — HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) — Ranger Oil Corporation (“Ranger” or the “Company”) (NASDAQ: ROCC) today announced financial and operational results for the fourth quarter and full-year 2021, its near-term plans for shareholder return initiatives through share repurchases and quarterly dividends, and the Company’s 2022 outlook. Significant Highlights Fourth QuarterSold 27,516 barrels of oil per day (“bbl/d”) for the fourth quarter of 2021, exceeding the mid-point of upward revised oil sales guidance. Total sales volumes were 40,236 barrels of oil equivalent per day (“boe/d”); Reported net income of $68 million and adjusted net income(1) of...

Denver, CO, March 07, 2022 (GLOBE NEWSWIRE) — Intrepid Potash, Inc. (NYSE:IPI) (“Intrepid”, the “Company”, “we”, “us”, “our”) today reports its financial results for the fourth quarter and full year of 2021. Key Fourth Quarter and Full Year 2021 TakeawaysNet income of $223.9 million and $249.8 million in the fourth quarter and full year 2021, respectively, which includes the release of $215.9 million of valuation allowance for deferred tax assets Adjusted net income(1) of $8.0 million and $21.8 million in the fourth quarter and full year 2021, respectively. Recorded $7.0 million of tax expense in the fourth quarter and full-year 2021 as a result of the release of the valuation allowance against the deferred tax assets Adjusted EBITDA(1) of $24.8 million for the fourth...

Fourth Quarter ResultsTotal revenues of $36.1 million, a 32% year-over-year increase and an 11% increase compared to the third quarter of 2021 Net income of $1.7 million as compared to $8.6 million and $2.8 million in the fourth quarter of 2020 and the third quarter of 2021, respectively, and earnings per diluted share of $0.68; adjusted net income of $1.2 million and adjusted earnings per diluted share of $0.48 Adjusted EBITDA of $6.5 million, a $3.5 million improvement compared to the fourth quarter of 2020 and a $2.3 million improvement compared to the third quarter of 2021 Net cash provided by operating activities, free cash flow and free cash flow after distributions to non-controlling interest of $11.6 million, $11.1 million and $8.4 million, respectively, for the year ended December 31, 2021 $22.2 million in cash and $7.8 million...

 Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be presented in 1H 2022 Interim data from Phase 1b clinical trial of ETX-155 in subjects with photosensitive epilepsy to be presented in 1H 2022 Submitted Investigational New Drug (IND) application for ETX-155 to the U.S. Food and Drug Administration (FDA)’s psychiatry division SEATTLE and CAMBRIDGE, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today reported financial results and business highlights for the quarter...

FORT WORTH, Texas, March 07, 2022 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the fourth quarter 2021 and reaffirmed its 2022 outlook. The Company completed its business combination on August 21, 2020 and consequently, the following operational and financial data refer to the three months and year ended December 31, 2021 and the three months ended December 31, 2020 and the period from August 22, 2020 through December 31, 2020 (the “Successor periods”) and the period from January 1, 2020 through August 21, 2020 (the “Predecessor period”). Fourth Quarter 2021 and Early 2022 HighlightsFourth quarter 2021 sales volumes of 14,881 barrels of crude oil equivalent per day (“Boe/d”), an increase of approximately 81% compared with third quarter...

– Sales in the Fourth Quarter of 2021 Increased 56% Year-Over-Year to a Record $118.2 Million; Sales for the Full Year 2021 Increased 68% to a Record $375.8 Million – – Expects Full Year 2022 Sales of $470.0 Million and Adjusted EBITDA of $78.0 Million – – Expects Full Year 2022 Free Cash Flow of $50.0 to $60.0 Million – SALT LAKE CITY, Utah, March 07, 2022 (GLOBE NEWSWIRE) — Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor and consumer enthusiast markets, reported financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Financial Summary vs. Same Year‐Ago QuarterRecord sales of $118.2 million increased 56%. Gross margin improved 60 basis points to 36.1%; adjusted gross margin increased by 120 basis points to 37.2%. Net income...

–Fourth quarter 2021 revenue and Adjusted EBITDA above previous guidance –2022 financial outlook highlights solid operating momentum and financial position CHARLOTTE, N.C., March 07, 2022 (GLOBE NEWSWIRE) — AvidXchange Holdings, Inc. (Nasdaq: AVDX), a leading provider of accounts payable (AP) automation software and payment solutions for middle market businesses and their suppliers, today announced financial results for the fourth quarter and full year ended December 31, 2021. “2021 was an extraordinary year for AvidXchange. We completed our transition to a public company and raised a significant amount of strategic capital while ending the year with solid operating results that outperformed expectations. We believe our across-the-board strong fourth quarter and full year 2021 results and outperformance relative to...

Rover – Bookings + GBV Rover – Bookings + GBVFourth quarter revenue increases to $38 million, up 41% from fourth quarter 2019 Record fourth quarter GBV of $166 million, up 44% from fourth quarter 2019 Fourth quarter new bookings of 215,000, up 30% from fourth quarter 2019SEATTLE, March 07, 2022 (GLOBE NEWSWIRE) — Rover Group, Inc. (“Rover”) (NASDAQ: ROVR), the world’s largest online marketplace for pet care, today announced financial results for the fourth quarter and full year ended December 31, 2021. “I am thrilled with the results our team delivered in a challenging and unpredictable year. We ended 2021 performing better than expected across key metrics such as revenue, unit economics, and Adjusted EBITDA,” said Rover co-founder and CEO, Aaron Easterly. “While we now believe pandemic dynamics will persist well...